Roche NimbleGen Microarrays Selected for the Neuromuscular Disorder -Chip Consortium
News Feb 27, 2009
The NMD-Chip Consortium, an initiative of the Seventh Framework Programme for Research and Technological Development, recently selected Roche NimbleGen microarrays to accelerate and simplify genetic research of neuromuscular disorders (NMDs).
The NMD-Chip Consortium is comprised of 13 European entities from eight countries whose goal is to further our understanding of NMDs and to investigate the possibilties of developing a faster, more cost-effective investigation and diagnosis (72 hours to one week versus the current time of two weeks to one year) in the future.
Pr Nicolas Levy, University of the Mediterranée and French National Institute for Health and Medical Research (INSERM), cites the importance of the Roche NimbleGen solution for NMD research: "As the European coordinator of the NMD-Chip project, I surely rely on Roche NimbleGen's very high density array technology, which is the most powerful tool to fulfill our project goals. Combined with our new bioinformatics tools, such technologies should completely renew our point of view on NMDs, by providing fast, reliable and accurate answers, at a much lower cost than ever before."
Inherited NMDs form a very large and diverse group of genetic diseases that cause progressive degeneration of the muscles and/or motor nerves that control movements. An estimated 1 out of 1,000 people may have a disabling inherited neuromuscular disease. The NMD-Chip Consortium aims to foster the research on NMDs by using a gene candidate approach to assess known forms as well as to characterize unknown forms of these disorders.
The Consortium will use custom designed NimbleGen Human CGH (Comparative Genomic Hybridization) 12x135K microarrays to enable them to locate gene- and exon-level rearrangements, deletions, or insertions associated with a specific NMD, namely Duchenne/Becker muscular dystrophies, limb girdle muscular dystrophies, congenital muscular dystrophies, and hereditary motor-sensory neuropathies or Charcot-Marie-Tooth neuropathies.
These high-throughput CGH arrays are expected to speed discovery by allowing 12 research samples to be processed at the same time on a single array which will also reduce the cost per sample.
In addition, the Consortium will use customized NimbleGen Human Sequence Capture 385K arrays to capture DNA fragments of all known genes implied in a given group of NMDs. This technology when coupled with high-throughput sequencing like 454 sequencing will provide quick evaluation of the gene variation underlying the NMDs being researched.
PhoreMost Completes $15M (£11M) Series-A Round to Enter Drug DiscoveryNews
Investment to fund expansion of operations and progression of drug target pipeline.READ MORE
Algorithm Predicts Life Expectancy After Heart AttackNews
A new algorithm developed by UCLA researchers more accurately predicts which people will survive heart failure, and for how long, whether or not they receive a heart transplant. The algorithm would allow doctors to make more personalized assessments of people who are awaiting heart transplants, which in turn could enable health care providers to make better use of limited life-saving resources and potentially reduce health care costs.
Computation and Chemistry Combine to Create World-First Auxetic ProteinNews
A team of chemists at the University of California, San Diego (UCSD) has now designed a two-dimensional protein crystal that toggles between states of varying porosity and density. This is a first in biomolecular design that combined experimental studies with computation done on supercomputers. The research, published in April 2018 in Nature Chemistry, could help create new materials for renewable energy, medicine, water purification, and more.
Comments | 0 ADD COMMENT
9th International Conference on Mass Spectrometry and Chromatography
Sep 21 - Sep 22, 2018